Skip to main content
Contact Us
Subscribe
E-Edition
53°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AC Immune S.A.
(NQ:
ACIU
)
3.860
+0.170 (+4.61%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 11, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AC Immune S.A.
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
December 01, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
November 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
October 27, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 17, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
October 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 28, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
June 27, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
April 28, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
April 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
March 20, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
March 08, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the SVB Securities Global Biopharma Conference
February 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
January 26, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
January 18, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
November 30, 2022
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
November 23, 2022
From
AC Immune SA
Via
GlobeNewswire
Is Ardelyx is A Buy After Slip in Early 2022
November 21, 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Via
MarketBeat
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.